Company Overview

Corporate Profile
Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its late-stage product candidate, voxelotor (GBT440), for the treatment of sickle cell disease.
Stock Quote
GBT (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Down 0.1 (0.24%)
Data as of 07/20/18 4:00 p.m. ET
Refresh quote
Featured Events
Corporate Presentation
There are currently no items available.
Recent NewsMore >>
07/03/18GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., July 03, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that, on July 2, 2018, the compensation committee of the Company’s board of directors granted four new employees options to purchase an aggregate of 6,500 shares of the Company’s common stock with a per share exercise price of $42.90, the closing trading price on the grant date, and restricted stock units for an aggregate of 4,300 shares of the Company’s common stoc... 
Printer Friendly Version
06/27/18GBT Announces Positive Top-line Data from Part A of the Phase 3 HOPE Study of Voxelotor in Sickle Cell Disease
Primary Endpoint Achieved; 58 Percent of Patients on Voxelotor Dosed with 1500 mg at Week 12 Exceeded 1 g/dL Increase in Hemoglobin Versus 9 Percent of Placebo (p<0.0001) Company Met with FDA on June 25 and Is in Discussions on Potential Accelerated Approval Based on Hemolytic Anemia Efficacy as Assessed by Primary Endpoint Numerically Fewer Vaso-occlusive Crisis (VOC) Episodes in Each Voxelotor Arm Versus Placebo GBT to Host Conference Call and Webcast Today, Wednesday, June 27, at 5:30 ... 
Printer Friendly Version
06/15/18GBT Announces New Phase 2a Voxelotor Data in Adolescents with Sickle Cell Disease (SCD) at 23rd European Hematology Association (EHA) Congress
Data from Four Additional Posters to be Presented, Including New Pharmacokinetic Data from HOPE-KIDS 1 Study Supporting Use of Weight-based Dosing Strategy for Voxelotor Clinical Trials in Children SOUTH SAN FRANCISCO, Calif., June 15, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced new 24-week data from patients treated with the 900 mg dose of voxelotor in the ongoing HOPE-KIDS 1 Study, a Phase 2a open-label study in adolescents ages 6 to 17 years ... 
Printer Friendly Version
06/08/18GBT Announces Upcoming Data Presentations Supporting Voxelotor Sickle Cell Disease (SCD) Program at Foundation for Sickle Cell Disease Research’s 12th Annual Symposium
SOUTH SAN FRANCISCO, Calif., June 08, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that four abstracts related to the voxelotor program in sickle cell disease will be presented during the Foundation for Sickle Cell Disease Research’s (FSCDR) 12th Annual SCD Research and Educational Symposium in Washington, D.C., taking place June 15-17, 2018. Four encore abstracts have been accepted, including three for oral presentation. Additionally, Kenneth R. ... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Global Blood Therapeutics Inc posts new information to the site. Just enter your e-mail address and click Submit.
Data provided by Nasdaq. Minimum 15 minutes delayed.